We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Stefano Gullà is the Co-founder and CEO of Abcuro Inc., a biotech startup focused on developing first-in-class therapeutic antibodies for immuno-oncology and autoimmunity indications. Prior to his role at Abcuro, Stefano led several drug discovery programs from target validation to clinical stage as a Program Leader at Pfizer and later at Agenus managing a portfolio of early stage assets. He brings to Abcuro a track record of pharma industry leadership, program management and drug discovery experience. Stefano is trained in biophysics and protein engineering at Northeastern University and MIT.
This speaker's sessions: